Most recent stories in Misc
http://www.lifehack.org/articles/lifestyle/10-things-wish-known-before-having-baby.html?n=1&ref=tp
http://www.fool.com/investing/general/2015/02/22/the-10-billion-reason-that-this-tiny-biotech-stock.aspx
Portola Pharmaceuticals (NASDAQ: PTLA ) recently announced that its phase 3 trial for its factor Xa anticoagulant betrixaban will complete enrollment by year end. If Portola can demonstrate that betrixaban can control bleeding in hospital and post-discharge patients, it could become a big player in the $10 billion market for anticoagulants.
See more stories
Misc
Magazine